Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Golden Throat Holdings Group Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Golden Throat Holdings Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Golden Throat Holdings Group Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Golden Throat Holdings Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Golden Throat Holdings Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Golden Throat Holdings Group Co (HKSE:06896) has a FCF Margin % of 11.97% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Golden Throat Holdings Group Co and its competitors. This is near median its historical median of 11.89. According to the industry distribution chart, Golden Throat Holdings Group Co ranks #317 out of 963 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is Golden Throat Holdings Group Co's FCF Margin % too high?
Golden Throat Holdings Group Co's current FCF Margin % of 11.97% is near median its 10-year median of 11.89. The Drug Manufacturers industry median FCF Margin % is 2.57. Golden Throat Holdings Group Co's value of 11.97% is 365.8% above this industry median. Based on the distribution chart, Golden Throat Holdings Group Co ranks #317 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Golden Throat Holdings Group Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Golden Throat Holdings Group Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Golden Throat Holdings Group Co ranks #317 out of 963 companies for FCF Margin %. This puts Golden Throat Holdings Group Co in the upper half of its industry. The industry median FCF Margin % is 2.57. Golden Throat Holdings Group Co's value of 11.97% is 365.8% above this benchmark. While the company's 10-year median is 11.89 vs. the industry median of 2.57, Golden Throat Holdings Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Golden Throat Holdings Group Co's current FCF Margin % of 11.97% is 365.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Golden Throat Holdings Group Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Golden Throat Holdings Group Co's current FCF Margin % is 11.97%, which is near median its own 10-year median of 11.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Golden Throat Holdings Group Co stock overvalued right now?
Based on GuruFocus' analysis, Golden Throat Holdings Group Co (HKSE:06896) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$2.98, compared to a current price of HK$2.27 — trading 24% below its estimated fair value. The current FCF Margin % is 11.97%, which is near median its 10-year median of 11.89 and 365.8% above the Drug Manufacturers industry median of 2.57. Golden Throat Holdings Group Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Golden Throat Holdings Group Co (HKSE:06896), the current FCF Margin % is 11.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Golden Throat Holdings Group Co (HKSE:06896) Overvalued in 2026?
Based on GuruFocus' analysis, Golden Throat Holdings Group Co stock appears to be undervalued.
The current stock price of HK$2.27 is trading 24% below its estimated GF Value™ of HK$2.98.
GuruFocus considers Golden Throat Holdings Group Co to be Modestly Undervalued.
Key valuation signals for HKSE:06896:
FCF Margin %: 11.97% (near median its 10-year median of 11.89)
GF Value™: HK$2.98 vs. price of HK$2.27 (24% below fair value)
Industry Position: 365.8% above the Drug Manufacturers median (#317 of 963)
No single metric tells the full story. See the HKSE:06896 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Golden Throat Holdings Group Co Ltd is an investment holding company. Through its subsidiaries, the company is engaged in the manufacture and sale of pharmaceuticals, healthcare food and other products. The compqny manufactures and sells lozenges and other pharmaceutical and food products. The key products of the group that derives revenue for the group are Golden Throat Lozenges (OTC), Golden Throat Lozenge Series products and other products. The group derives majority of its revenue from Mainland China.
83GF Score
Get the complete analysis for HKSE:06896
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06896 has been successfully added to your 
